← Back to Search

Wellness of Osteopathic Medical Students Throughout Their Training (Well-COM) (Well-COM Trial)

N/A
Recruiting
Led By Patrick Davis
Research Sponsored by Sam Houston State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Medical student enrolled in SHSU college of osteopathic medicine.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change over 10 years
Awards & highlights
No Placebo-Only Group

Summary

The Well-COM Research Project addresses a critical gap in our understanding of the holistic health of medical students, over the entirety of the medical school experience. While the rigorous demands of medical education and its effects on the well-being of medical students are well-documented, there is a lack of long-term study assessing the mental, physical, and metabolic health of medical students from entry into medical school through their training and into residency. By collecting holistic health data from new first-year medical students, and over a minimum period of 10 years, the Well-COM project aims to provide invaluable insights into the changes in health and wellness experienced by medical students, thereby informing future interventions and support systems to promote overall health and resilience in medical school students.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change over 10 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and change over 10 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Blood pressure
Body Fat Percentage
Burnout Index
+6 more

Side effects data

From 2023 Phase 2 trial • 1380 Patients • NCT05004181
18%
Headache
12%
Cough
12%
Nasal congestion
12%
Fatigue
6%
Ageusia
6%
COVID-19
6%
Oropharyngeal pain
6%
Nausea
6%
Upper respiratory tract infection
6%
Diarrhoea
6%
Arthralgia
6%
Anosmia
6%
Musculoskeletal chest pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Part A - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2)
Part A - Cohort 5: 1 Dose of 30 μg BNT162b2 (Original Vaccine)
Part C - Cohort 7: 1 Dose of 30 μg BNT162b2 (B.1.1.529)
Part A - Cohort 2: 2 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2)
Part B - Cohort 6: 3 Doses of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2)
Part A - Cohort 1: 1 Dose of 30 μg BNT162b2 (B.1.1.7 + B.1.617.2)
Part B - Cohort 4: 1 Dose 30 μg BNT162b2 (B.1.617.2)
Part A - Cohort 3: 1 Dose of 30 μg BNT162b2 (B.1.1.7)
Part A - Cohort 4: 1 Dose of 30 μg BNT162b2 (B.1.617.2)
Part B - Cohort 1: 1 Dose 30 μg BNT162b2 (B.1.1.7 + B.1.617.2)
Part C - Cohort 8: 1 Dose of 30 μg BNT162b2 (Original Vaccine)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: Class of 2031Experimental Treatment1 Intervention
Group II: Class of 2030Experimental Treatment1 Intervention
Group III: Class of 2029Experimental Treatment1 Intervention
Group IV: Class of 2028Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Sam Houston State UniversityLead Sponsor
5 Previous Clinical Trials
514 Total Patients Enrolled
Patrick DavisPrincipal InvestigatorSam Houston State University
~433 spots leftby Dec 2034